查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
老龄化黄斑部病变(AMD) 治疗的全球市场：按产品、分子、核准类型、AMD 类型和最终用户 - 预测（至 2029 年）
市场调查报告书
商品编码
1565358

老龄化黄斑部病变(AMD) 治疗的全球市场：按产品、分子、核准类型、AMD 类型和最终用户 - 预测（至 2029 年）

Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 336 Pages | 订单完成后即时交付

价格

全球老龄化黄斑部病变（AMD）治疗市场规模预计将从 2024 年的 104.6 亿美元增至 2029 年的 173.7 亿美元，复合年增长率预计为 10.7%。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 美元
部分 按产品、按分子、按 AMD 类型、按核准类型、按最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

大型製药公司报告称，到 2050 年，老年人口（60 岁以上）将翻一番，并且由于 AMD 与老年有关，这一增长将影响 AMD 患者的数量。吸烟、饮食和体力活动等生活习惯也会大大影响 AMD 风险。例如，研究表明，吸烟会使AMD的发病时间平均加速5.5年。根据英国黄斑部协会的数据，吸烟者可能比不吸烟者早 10 年患有 AMD。阿联酋和英国的领先眼科医生报告称，AMD 的发病年龄有所下降，并得出结论，不健康的生活习惯可能会在未来十年进一步推低这一年龄。日本研究人员调查了酒精对 AMD 的影响，并得出结论，中度至大量饮酒会增加早期 AMD 的风险。同样，较高的体重指数 (BMI) 会增加早期和晚期 AMD 的风险，因为肥胖和缺乏身体活动会导致氧化压力和发炎增加，从而促进 AMD 的发展。 AMD 的日益普及促使公司寻求简审类，以扩大其治疗管道并提高其产品的可用性。例如，2021年，Opthea Limited的管道药物OPT-302获得了简审类，该药物是为治疗湿性AMD患者而开发的，从而推进了开发进程。同样，到 2023 年，Adverum Biotechnology 的管道药物 Ixo-vec（ixoberogene soroparvovec）获得了英国MHRA 的创新护照，有助于加快英国的患者获取和监管支持。这些进展以及 AMD 患者数量的增加预计将增加 AMD 治疗的市场需求。

“Vabysmo 药物预计将在 2024 年至 2029 年创下市场最高增长纪录。”

由于患者和眼科医师对 AMD 治疗的正面回馈，预计 Vabysmo (faricimab-svoa) 在 2024-2029 年预测期内将达到最高成长率。该药物的日益普及也得益于 2022 年至 2023 年药品收益成长 4 倍。检验该药物疗效和耐受性的研究表明，该药物在视网膜疾病患者中耐受性良好，可以让患者保持视力，同时减少注射频率，从而减轻负担。该药物也用于治疗对 Eylea（阿柏西普）治疗产生抗药性的患者，并显示视力的显着改善。

“从最终用户来看，医院在市场上表现出高速成长。”

预计 2024 年至 2029 年预测期内，医院将呈现最高成长率。这种增长的部分原因在于医院有能力透过先进的医疗基础设施和专业治疗设施为患者提供全面的护理。此外，医院的数量超过任何其他最终用户（专科中心和长期护理机构），而现代医院通常是提供专业护理的多学科医院。医院通常与长期照护 (LTC) 机构合作，提供眼科医生等支持，为护理机构中的患者提供治疗。此外，医院也与製药公司合作，为患者提供最佳的AMD治疗方法。

本报告研究并分析了全球老龄化黄斑部病变(AMD) 治疗市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 老龄化黄斑部病变（AMD）治疗市场概述
  • 北美老龄化黄斑部病变(AMD) 治疗的市场占有率：按核准类型和国家/地区划分（2023 年）
  • 老龄化黄斑部病变(AMD) 治疗药物市场：依 AMD 类型划分（2024 年和 2029 年）
  • 老龄化黄斑部病变(AMD) 治疗市场：依最终使用者划分（2023 年）
  • 老龄化黄斑部病变（AMD）治疗市场：地理成长机会

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 技术分析
    • 主要技术
    • 邻近技术
  • 影响客户业务的趋势/干扰
  • 价格分析
    • 老龄化黄斑部病变（AMD）治疗药物的平均价格：以产品（每剂）
    • 老龄化黄斑部病变（AMD）治疗药物的平均价格：按地区
    • 老龄化黄斑部病变（AMD）治疗药物的平均售价：按主要企业划分
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 专利分析
  • 监管分析
    • 监管环境
    • 监管机构、政府机构和其他组织
  • 波特五力分析
  • 重大会议和活动（2024-2025）
  • 主要相关利益者和采购标准
  • 投资/资金筹措活动
  • 管道分析
  • 案例研究分析
  • 人工智慧对老龄化黄斑部病变（AMD）治疗市场的影响

老龄化黄斑部病变（AMD）治疗药物市场：副产品

  • 介绍
  • 艾莉亚，艾莉亚高清
  • LUCENTIS
  • VABYSMO
  • SYFOVRE
  • 其他产品

老龄化黄斑部病变(AMD) 治疗市场：依分子分类

  • 介绍
  • 阿柏西普
  • 法瑞昔单抗
  • 雷珠单抗
  • 佩杰塔科计划
  • 其他分子

第 8 章老龄化黄斑部病变(AMD) 治疗药物市场：依核准类型

  • 介绍
  • 生物製药
  • 生物相似药

第 9 章老龄化黄斑部病变(AMD) 治疗药物市场：依 AMD 类型

  • 介绍
  • 湿性AMD
  • 干性AMD

第 10 章老龄化黄斑部病变(AMD) 治疗药物市场：依最终使用者分类

  • 介绍
  • 医院
  • 长期照护设施
  • 专业中心

老龄化黄斑部病变（AMD）治疗药物市场：按地区

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东
    • 中东宏观经济展望
    • 海湾合作委员会国家
    • 其他中东地区
  • 非洲

第十二章竞争格局

  • 概述
  • 主要企业策略/主要企业
  • 收益分析（2021-2023）
  • 市场占有率分析（2023）
  • 企业评价矩阵：主要企业（2023年）
  • 企业评估矩阵：Start-Ups/中小企业（2023）
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十三章 公司简介

  • 主要企业
    • F. HOFFMANN-LA ROCHE LTD
    • REGENERON PHARMACEUTICALS INC.
    • NOVARTIS AG
    • BAYER AG
    • APELLIS PHARMACEUTICALS
    • ASTELLAS PHARMA INC.
    • STADA ARZNEIMITTEL AG
    • BIOGEN
    • FORMYCON AG
    • COHERUS BIOSCIENCES
    • BIOCON
    • OUTLOOK THERAPEUTICS, INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • INTAS PHARMACEUTICALS LTD.
    • SANDOZ GROUP AG
    • CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
  • 其他公司
    • OCULAR THERAPEUTIX, INC.
    • OPTHEA LIMITED
    • KODIAK SCIENCES INC.
    • BIO-THERA
    • AMGEN INC.
    • ALVOTECH
    • STEALTH BIOTHERAPEUTICS INC.
    • ALTEOGEN INC.
    • OCUMENSION THERAPEUTICS
    • INNOVENT
    • SHANGHAI HENLIUS BIOTECH, INC.

第十四章附录

Product Code: PH 9145

The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, Molecule, Type of AMD, Approval type, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK's MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.

"Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market"

Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.

"Hospitals to witness the high growth in the AMD drugs market by End User"

Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.

"Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type"

Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.

"North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market"

The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side -70% and Demand Side - 30%
  • By Designation: Managers -45%, CXOs and Directors -30%, and Executives - 25%
  • By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%

Lists of Companies Profiled in the Report:

  • Regeneron Pharmaceuticals Inc. (US)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Apellis Pharmaceuticals (US)
  • Coherus BioSciences (US)
  • Astellas Pharma Inc. (Japan)
  • Biogen (US)
  • STADA Arzneimittel AG (Germany)
  • Formycon AG (Germany)
  • Biocon. (India)
  • Outlook Therapeutics, Inc. (US)
  • Intas Pharmaceuticals Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Chengdu Kanghong Biotech Company (China)
  • Sandoz Group AG (Switzerland)
  • Stealth BioTherapeutics Inc. (US)
  • Ocular Therapeutix, Inc. (US)
  • Opthea Limited (Australia)
  • Kodiak Sciences Inc. (US)
  • Innovent Biologics, Inc. (China)
  • Bio-Thera Solution (China)
  • Alvotech (Iceland)
  • Alteogen Inc. (South Korea)
  • Shanghai Henlius Biotech, Inc. (China)
  • Amgen Inc. (US)
  • Ocumension Therapeutics. (China)
  • Adverum Biotechnologies, Inc. (US)

Research Coverage:

This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
  • 2.3 MARKET GROWTH FORECAST
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
  • 4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
  • 4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
  • 4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
  • 4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Changing lifestyle and dietary habits
      • 5.2.1.2 Steady development and approvals of drugs
      • 5.2.1.3 Favorable reimbursement and insurance policies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Off-label use of drugs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Shifting focus on new drug modalities
      • 5.2.3.2 Rapidly expanding market in developing countries
      • 5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Non-adherence to treatments
  • 5.3 TECHNOLOGY ANALYSIS
    • 5.3.1 KEY TECHNOLOGIES
      • 5.3.1.1 Hybridoma technology
      • 5.3.1.2 Recombinant DNA technology
      • 5.3.1.3 Antibody engineering
    • 5.3.2 ADJACENT TECHNOLOGIES
      • 5.3.2.1 Tissue engineering (scaffold technology)
      • 5.3.2.2 Artificial intelligence
      • 5.3.2.3 Optogenetic technology
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
    • 5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
    • 5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
  • 5.9 PATENT ANALYSIS
  • 5.10 REGULATORY ANALYSIS
    • 5.10.1 REGULATORY LANDSCAPE
      • 5.10.1.1 US
      • 5.10.1.2 Europe
      • 5.10.1.3 Emerging economies
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.11.2 BARGAINING POWER OF SUPPLIERS
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 THREAT OF SUBSTITUTES
    • 5.11.5 THREAT OF NEW ENTRANTS
  • 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 BUYING CRITERIA
  • 5.14 INVESTMENT/FUNDING ACTIVITY
  • 5.15 PIPELINE ANALYSIS
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
    • 5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
    • 5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT
  • 5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET

6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 EYLEA & EYLEA HD
    • 6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS TO SPEED UP GROWTH
  • 6.3 LUCENTIS
    • 6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL THICKNESS TO FAVOR GROWTH
  • 6.4 VABYSMO
    • 6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES TO SUSTAIN GROWTH
  • 6.5 SYFOVRE
    • 6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED MACULAR DEGENERATION TO BOOST MARKET
  • 6.6 OTHER PRODUCTS

7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE

  • 7.1 INTRODUCTION
  • 7.2 AFLIBERCEPT
    • 7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS TO EXPEDITE GROWTH
  • 7.3 FARICIMAB
    • 7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH STUDIES TO AUGMENT GROWTH
  • 7.4 RANIBIZUMAB
    • 7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
  • 7.5 PEGCETACOPLAN
    • 7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO CONTRIBUTE TO GROWTH
  • 7.6 OTHER MOLECULES

8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE

  • 8.1 INTRODUCTION
  • 8.2 BIOLOGICS
    • 8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES TO SUPPORT GROWTH
  • 8.3 BIOSIMILARS
    • 8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH

9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD

  • 9.1 INTRODUCTION
  • 9.2 WET AMD
    • 9.2.1 GROWING GERIATRIC POPULATION TO FACILITATE GROWTH
  • 9.3 DRY AMD
    • 9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH

10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
  • 10.4 SPECIALTY CENTERS
    • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Rising investment in healthcare research & development to propel market
    • 11.2.3 CANADA
      • 11.2.3.1 Favorable government initiatives to aid market growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth
    • 11.3.3 UK
      • 11.3.3.1 Ongoing technological advancements to promote growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth
    • 11.3.5 ITALY
      • 11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market
    • 11.3.6 SPAIN
      • 11.3.6.1 Growing number of collaborative projects to favor market growth
    • 11.3.7 NETHERLANDS
      • 11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
    • 11.3.8 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Strategic drug approvals to support market growth
    • 11.4.3 JAPAN
      • 11.4.3.1 Advanced healthcare infrastructure to encourage growth
    • 11.4.4 INDIA
      • 11.4.4.1 Regulatory reforms and aging population to boost market
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Supportive regulatory environment to boost market
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Increasing rate of visual impairment to sustain growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Saudi Arabia
        • 11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market
      • 11.6.2.2 UAE
        • 11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
      • 11.6.2.3 Other GCC Countries
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • 12.3 REVENUE ANALYSIS, 2021-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Molecule footprint
      • 12.5.5.3 Approval footprint
      • 12.5.5.4 Type of AMD footprint
      • 12.5.5.5 Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 12.7.1 COMPANY VALUATION
    • 12.7.2 FINANCIAL METRICS
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches & approvals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses and competitive threats
    • 13.1.2 REGENERON PHARMACEUTICALS INC.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches & approvals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 NOVARTIS AG
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches & approvals
        • 13.1.3.3.2 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 BAYER AG
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product launches & approvals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 APELLIS PHARMACEUTICALS
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches & approvals
        • 13.1.5.3.2 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
          • 13.1.5.4.2.1 Weaknesses and competitive threats
    • 13.1.6 ASTELLAS PHARMA INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches & approvals
        • 13.1.6.3.2 Deals
    • 13.1.7 STADA ARZNEIMITTEL AG
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches & approvals
        • 13.1.7.3.2 Deals
    • 13.1.8 BIOGEN
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product launches & approvals
    • 13.1.9 FORMYCON AG
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches & approvals
        • 13.1.9.3.2 Deals
    • 13.1.10 COHERUS BIOSCIENCES
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Products launches & approvals
        • 13.1.10.3.2 Other developments
    • 13.1.11 BIOCON
      • 13.1.11.1 Business overview
      • 13.1.11.2 Product offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product launches & approvals
        • 13.1.11.3.2 Deals
    • 13.1.12 OUTLOOK THERAPEUTICS, INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product launches & approvals
        • 13.1.12.3.2 Deals
    • 13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Product launches & approvals
        • 13.1.13.3.2 Deals
    • 13.1.14 INTAS PHARMACEUTICALS LTD.
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
    • 13.1.15 SANDOZ GROUP AG
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product launches & approvals
        • 13.1.15.3.2 Deals
        • 13.1.15.3.3 Expansions
    • 13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
  • 13.2 OTHER PLAYERS
    • 13.2.1 OCULAR THERAPEUTIX, INC.
    • 13.2.2 OPTHEA LIMITED
    • 13.2.3 KODIAK SCIENCES INC.
    • 13.2.4 BIO-THERA
    • 13.2.5 AMGEN INC.
    • 13.2.6 ALVOTECH
    • 13.2.7 STEALTH BIOTHERAPEUTICS INC.
    • 13.2.8 ALTEOGEN INC.
    • 13.2.9 OCUMENSION THERAPEUTICS
    • 13.2.10 INNOVENT
    • 13.2.11 SHANGHAI HENLIUS BIOTECH, INC.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • TABLE 2 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE), 2021-2023 (USD)
  • TABLE 4 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER, 2021-2023 (USD)
  • TABLE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 6 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
  • TABLE 7 INNOVATIONS AND PATENT REGISTRATIONS, 2019-2023
  • TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 15 BUYING CRITERIA FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER
  • TABLE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS IN CLINICAL PIPELINE, PHASE 3
  • TABLE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 18 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2023-2029 (MILLION UNITS)
  • TABLE 19 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 20 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 21 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 25 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 55 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 56 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 61 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 75 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 89 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 91 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 98 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 106 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 107 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 121 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 122 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 127 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 135 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 143 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 145 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 146 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN NORTH AMERICA
  • TABLE 150 US HEALTHCARE SPENDING, 2020-2022 (USD MILLION)
  • TABLE 151 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 152 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 153 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 155 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 156 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 157 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 158 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 160 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 161 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 162 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 163 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 165 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 166 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN EUROPE
  • TABLE 168 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 169 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 170 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 172 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 173 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 174 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 175 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 176 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 177 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 178 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 179 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 180 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 182 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 183 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 184 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 185 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 187 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 188 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 189 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 190 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 191 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 192 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 193 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 194 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 195 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 197 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 198 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 199 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 200 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 202 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN ASIA PACIFIC
  • TABLE 210 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 211 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 212 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 214 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 215 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 216 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 217 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 219 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 220 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 221 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 222 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 224 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 225 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 226 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 227 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 228 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 229 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 230 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 231 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 232 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 233 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 234 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 235 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 237 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 240 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 241 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 243 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 245 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 246 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN LATIN AMERICA
  • TABLE 247 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 248 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 249 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 251 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 252 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 253 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 254 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 255 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 256 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 259 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 261 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 262 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 263 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 264 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 265 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 266 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 267 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 268 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN MIDDLE EAST
  • TABLE 269 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 270 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 271 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 273 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 274 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 275 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 276 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 277 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 279 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 280 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 281 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 282 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 284 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 285 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 286 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 287 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 289 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 290 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 291 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 292 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 294 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 295 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 296 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
  • TABLE 297 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
  • TABLE 298 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
  • TABLE 299 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 300 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN AFRICA
  • TABLE 301 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • TABLE 302 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEGREE OF COMPETITION
  • TABLE 303 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: MOLECULE FOOTPRINT
  • TABLE 304 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: APPROVAL TYPE FOOTPRINT
  • TABLE 305 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: TYPE OF AMD FOOTPRINT
  • TABLE 306 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REGION FOOTPRINT
  • TABLE 307 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 308 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 309 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 310 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEALS, JANUARY 2021- AUGUST 2024
  • TABLE 311 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 313 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 314 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 315 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 316 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
  • TABLE 317 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 318 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 319 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 320 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 321 NOVARTIS AG: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 322 BAYER AG: COMPANY OVERVIEW
  • TABLE 323 BAYER AG: PRODUCTS OFFERED
  • TABLE 324 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 325 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 326 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 327 APELLIS PHARMACEUTICALS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 328 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 329 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 330 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 331 ASTELLAS PHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 332 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 333 STADA ARZNEIMITTEL AG: COMPANY OVERVIEW
  • TABLE 334 STADA ARZNEIMITTEL AG: PRODUCTS OFFERED
  • TABLE 335 STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 336 STADA ARZNEIMITTEL AG: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 337 BIOGEN: COMPANY OVERVIEW
  • TABLE 338 BIOGEN: PRODUCTS OFFERED
  • TABLE 339 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 340 FORMYCON AG: COMPANY OVERVIEW
  • TABLE 341 FORMYCON AG: PRODUCTS OFFERED
  • TABLE 342 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 343 FORMYCON AG: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 344 COHERUS BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 345 COHERUS BIOSCIENCES: PRODUCTS OFFERED
  • TABLE 346 COHERUS BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 347 COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
  • TABLE 348 BIOCON: COMPANY OVERVIEW
  • TABLE 349 BIOCON: PRODUCTS OFFERED
  • TABLE 350 BIOCON: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 351 BIOCON: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 352 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 353 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 355 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 356 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 360 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
  • TABLE 361 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
  • TABLE 362 SANDOZ GROUP AG: COMPANY OVERVIEW
  • TABLE 363 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 364 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 365 SANDOZ GROUP AG: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 366 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 367 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
  • TABLE 368 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
  • TABLE 369 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
  • TABLE 370 OPTHEA LIMITED: COMPANY OVERVIEW
  • TABLE 371 KODIAK SCIENCES INC.: COMPANY OVERVIEW
  • TABLE 372 BIO-THERA: COMPANY OVERVIEW
  • TABLE 373 AMGEN INC.: COMPANY OVERVIEW
  • TABLE 374 ALVOTECH: COMPANY OVERVIEW
  • TABLE 375 STEALTH BIOTHERAPEUTICS INC.: COMPANY OVERVIEW
  • TABLE 376 ALTEOGEN INC.: COMPANY OVERVIEW
  • TABLE 377 OCUMENSION THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 378 INNOVENT: COMPANY OVERVIEW
  • TABLE 379 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
  • FIGURE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: COMPANY REVENUE SHARE ANALYSIS, 2023
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 8 BOTTOM-UP APPROACH
  • FIGURE 9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: CAGR PROJECTIONS, 2024-2029
  • FIGURE 10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
  • FIGURE 11 DATA TRIANGULATION
  • FIGURE 12 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF APPROVAL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2024-2029
  • FIGURE 18 GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLES TO DRIVE MARKET
  • FIGURE 19 BIOLOGICS SEGMENT AND US DOMINATED NORTH AMERICAN MARKET IN 2023
  • FIGURE 20 WET AMD SEGMENT TO LEAD MARKET BY 2029
  • FIGURE 21 HOSPITALS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 23 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 REVENUE SHIFT & NEW POCKETS FOR AGE-RELATED MACULAR DEGENERATION THERAPY PROVIDERS
  • FIGURE 25 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2021-2023 (USD)
  • FIGURE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 28 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 29 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PATENT ANALYSIS, 2014-2024
  • FIGURE 30 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS
  • FIGURE 32 KEY BUYING CRITERIA, BY END USER
  • FIGURE 33 IMPACT OF ARTIFICIAL INTELLIGENCE ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
  • FIGURE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
  • FIGURE 35 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 38 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 39 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY FOOTPRINT
  • FIGURE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 45 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2023)
  • FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2023)
  • FIGURE 50 BIOGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 51 FORMYCON AG: COMPANY SNAPSHOT (2023)
  • FIGURE 52 BIOCON: COMPANY SNAPSHOT (2023)
  • FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)